SCHEMBL21802147

SCHEMBL21802147

O=C(NCCCCN1CCN(c2cccc(Cl)c2)CC1)Nc1cnc2ccccc2c1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 7/20 0.66
HTR6 P50406 7/20 0.66
MAPT P10636 2/20 0.63
KMT2A Q03164 1/20 0.63
DRD3 P35462 6/20 0.63
KCNH2 Q12809 1/20 0.63
DRD2 P14416 6/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
PKM P14618 1/20 0.60
ADRA1A P35348 2/20 0.58
TP53 P04637 1/20 0.58
HTR2A P28223 2/20 0.57
HTR1A P08908 1/20 0.57
HTR2C P28335 1/20 0.57
DRD4 P21917 1/20 0.56
LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21802141 0.93 HTR7 (0.65) HTR7HTR6MAPTDRD3KCNH2
SCHEMBL21802152 0.89 SLC6A4 (0.60) HTR7HTR6DRD3DRD2ADRA1A
SCHEMBL21802153 0.89 TRPV1 (0.62) HTR7HTR6MAPTDRD3DRD2
SCHEMBL21802154 0.88 DRD2 (0.67) HTR7HTR6DRD3KCNH2DRD2
SCHEMBL21802015 0.88 DRD3 (0.56) HTR7HTR6MAPTDRD3DRD2
SCHEMBL21802155 0.87 DRD2 (0.75) HTR7HTR6DRD3KCNH2DRD2
SCHEMBL21802020 0.85 DRD3 (0.55) HTR7HTR6MAPTDRD3KCNH2
SCHEMBL21802095 0.84 LMNA (0.67) HTR7MAPTKMT2ADRD3DRD2
SCHEMBL21802148 0.83 DRD3 (0.59) HTR7HTR6MAPTDRD3DRD2
SCHEMBL21802018 0.82 LMNA (0.59) HTR7MAPTDRD3DRD2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319659-B2 Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof SHENZHEN LINGLAN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-06-03 US claimed
US-20200087264-A1 NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) 2020-03-19 US claimed
US-12319659-B2 Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof SHENZHEN LINGLAN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-06-03 US disclosed
US-20200087264-A1 NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) 2020-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087264-A1 NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF DRD3, DRD2, PRLHR HTR7 144/4885HTR6 121/4885MAPT 1794/4885
US-12319659-B2 Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof DRD3, DRD2, PRLHR HTR7 130/4885HTR6 168/4885MAPT 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.